Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126736191 | 12673619 | 1 | I | 20160817 | 20160822 | 20160822 | PER | US-PFIZER INC-2016393284 | PFIZER | 0.00 | F | Y | 0.00000 | 20160822 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126736191 | 12673619 | 1 | PS | PRISTIQ EXTENDED-RELEASE | DESVENLAFAXINE SUCCINATE | 1 | Oral | 150 MG, 1X/DAY | N39354 | 21992 | 150 | MG | PROLONGED-RELEASE TABLET | QD | |||||
126736191 | 12673619 | 2 | C | BIESTROGEN | 2 | 1 DF, 1X/DAY (BIEST 0.25 MG, ONE CAPSULE A DAY) | 0 | 1 | DF | QD | |||||||||
126736191 | 12673619 | 3 | C | PROGESTERONE. | PROGESTERONE | 1 | 100 MG, UNK | 0 | 100 | MG |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126736191 | 12673619 | 2 | Hormone replacement therapy |
126736191 | 12673619 | 3 | Hormone replacement therapy |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126736191 | 12673619 | Dizziness | |
126736191 | 12673619 | Eye pain | |
126736191 | 12673619 | Eye swelling | |
126736191 | 12673619 | Metamorphopsia | |
126736191 | 12673619 | Ocular discomfort | |
126736191 | 12673619 | Vertigo | |
126736191 | 12673619 | Visual impairment |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |